AbbVie 2014 Annual Report Download - page 167

Download and view the complete annual report

Please find page 167 of the 2014 AbbVie annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 182

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176
  • 177
  • 178
  • 179
  • 180
  • 181
  • 182

13NOV201221352027
If a change in control had occurred on December 31, 2014 and the surviving company did not assume, convert
or replace any of the awards granted after January 2013, then the unvested equity awards of the NEOs would have
vested as follows:
• Mr. Gonzalez would have vested in (i) 667,750 unvested AbbVie stock options with a value of $15,609,336
and 35,767 unvested Abbott stock options with a value of $643,320, and (ii) 354,573 shares of AbbVie
restricted stock with a value of $23,203,257 and 19,800 Abbott restricted shares with a value of $891,396.
• Dr. Severino would have vested in (i) 74,309 unvested AbbVie stock options with a value of $817,399, and
(ii) 141,625 shares of AbbVie restricted stock with a value of $9,267,940.
• Mr. Alban would have vested in (i) 174,753 unvested AbbVie stock options with a value of $4,005,808 and
16,033 unvested Abbott stock options with a value of $288,376, and (ii) 129,481 shares of AbbVie restricted
stock with a value of $8,473,236 and 8,900 Abbott restricted shares with a value of $400,678.
• Ms. Schumacher would have vested in (i) 217,746 unvested AbbVie stock options with a value of $5,150,621
and 26,600 unvested Abbott stock options with a value of $478,438, and (ii) 176,011 shares of AbbVie
restricted stock with a value of $11,518,161 and 14,733 Abbott restricted shares with a value of $663,280.
• Mr. Chase would have vested in (i) 176,493 unvested AbbVie stock options with a value of $3,819,398 and
6,533 unvested Abbott stock options with a value of $117,505, and (ii) 139,604 shares of AbbVie restricted
stock with a value of $9,135,686 and 3,633 Abbott restricted shares with a value of $163,558.
The value of stock options shown is based on the excess of the closing price of one share of common stock on
December 31, 2014 over the exercise price of such options, multiplied by the number of unvested stock options held by
the NEO. The value of restricted stock shown is determined by multiplying the number of restricted shares that would
vest as of December 31, 2014 and the closing price of one share of common stock on December 31, 2014.
2015 Proxy Statement 47
EXECUTIVE COMPENSATION